vs
Side-by-side financial comparison of APTARGROUP, INC. (ATR) and EXELIXIS, INC. (EXEL). Click either name above to swap in a different company.
APTARGROUP, INC. is the larger business by last-quarter revenue ($982.9M vs $598.7M, roughly 1.6× EXELIXIS, INC.). EXELIXIS, INC. runs the higher net margin — 40.8% vs 7.4%, a 33.4% gap on every dollar of revenue. On growth, APTARGROUP, INC. posted the faster year-over-year revenue change (10.8% vs 5.6%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $53.3M). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 3.9%).
AptarGroup, Inc., also known as Aptar, is a United States–based global manufacturer of consumer dispensing packaging and drug delivery devices. The group has manufacturing operations in 18 countries.
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
ATR vs EXEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $982.9M | $598.7M |
| Net Profit | $72.8M | $244.5M |
| Gross Margin | — | 95.6% |
| Operating Margin | 10.9% | 39.3% |
| Net Margin | 7.4% | 40.8% |
| Revenue YoY | 10.8% | 5.6% |
| Net Profit YoY | -7.5% | 74.8% |
| EPS (diluted) | $1.12 | $0.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $982.9M | $598.7M | ||
| Q4 25 | $962.7M | $597.8M | ||
| Q3 25 | $961.1M | $568.3M | ||
| Q2 25 | $966.0M | $555.4M | ||
| Q1 25 | $887.3M | $566.8M | ||
| Q4 24 | $848.1M | — | ||
| Q3 24 | $909.3M | $539.5M | ||
| Q2 24 | $910.1M | $637.2M |
| Q1 26 | $72.8M | $244.5M | ||
| Q4 25 | $74.3M | $193.6M | ||
| Q3 25 | $127.9M | $184.8M | ||
| Q2 25 | $111.7M | $159.6M | ||
| Q1 25 | $78.8M | $139.9M | ||
| Q4 24 | $100.9M | — | ||
| Q3 24 | $100.0M | $118.0M | ||
| Q2 24 | $90.5M | $226.1M |
| Q1 26 | — | 95.6% | ||
| Q4 25 | — | 96.9% | ||
| Q3 25 | — | 96.6% | ||
| Q2 25 | — | 96.5% | ||
| Q1 25 | — | 96.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 96.8% | ||
| Q2 24 | — | 97.2% |
| Q1 26 | 10.9% | 39.3% | ||
| Q4 25 | 11.0% | 39.6% | ||
| Q3 25 | 14.2% | 37.6% | ||
| Q2 25 | 14.9% | 33.6% | ||
| Q1 25 | 12.8% | 28.8% | ||
| Q4 24 | 14.2% | — | ||
| Q3 24 | 15.2% | 25.2% | ||
| Q2 24 | 13.8% | 43.3% |
| Q1 26 | 7.4% | 40.8% | ||
| Q4 25 | 7.7% | 32.4% | ||
| Q3 25 | 13.3% | 32.5% | ||
| Q2 25 | 11.6% | 28.7% | ||
| Q1 25 | 8.9% | 24.7% | ||
| Q4 24 | 11.9% | — | ||
| Q3 24 | 11.0% | 21.9% | ||
| Q2 24 | 9.9% | 35.5% |
| Q1 26 | $1.12 | $0.89 | ||
| Q4 25 | $1.13 | $0.69 | ||
| Q3 25 | $1.92 | $0.65 | ||
| Q2 25 | $1.67 | $0.55 | ||
| Q1 25 | $1.17 | $0.47 | ||
| Q4 24 | $1.48 | — | ||
| Q3 24 | $1.48 | $0.40 | ||
| Q2 24 | $1.34 | $0.77 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $229.5M | $1.1B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.6B | $2.2B |
| Total Assets | $5.1B | $2.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $229.5M | $1.1B | ||
| Q4 25 | $409.5M | $988.5M | ||
| Q3 25 | $264.8M | $791.1M | ||
| Q2 25 | $169.8M | $1.0B | ||
| Q1 25 | $136.8M | $1.1B | ||
| Q4 24 | $226.2M | — | ||
| Q3 24 | $327.9M | $1.2B | ||
| Q2 24 | $223.9M | $1.0B |
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | — | ||
| Q3 25 | $546.0M | — | ||
| Q2 25 | $535.1M | — | ||
| Q1 25 | $561.2M | — | ||
| Q4 24 | $688.1M | — | ||
| Q3 24 | $822.7M | — | ||
| Q2 24 | $681.5M | — |
| Q1 26 | $2.6B | $2.2B | ||
| Q4 25 | $2.7B | $2.2B | ||
| Q3 25 | $2.8B | $2.0B | ||
| Q2 25 | $2.7B | $2.1B | ||
| Q1 25 | $2.5B | $2.2B | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | $2.3B | ||
| Q2 24 | $2.4B | $2.1B |
| Q1 26 | $5.1B | $2.8B | ||
| Q4 25 | $5.3B | $2.8B | ||
| Q3 25 | $5.1B | $2.7B | ||
| Q2 25 | $4.9B | $2.8B | ||
| Q1 25 | $4.5B | $2.9B | ||
| Q4 24 | $4.4B | — | ||
| Q3 24 | $4.6B | $3.0B | ||
| Q2 24 | $4.5B | $2.8B |
| Q1 26 | — | — | ||
| Q4 25 | 0.43× | — | ||
| Q3 25 | 0.20× | — | ||
| Q2 25 | 0.20× | — | ||
| Q1 25 | 0.22× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 0.32× | — | ||
| Q2 24 | 0.28× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $333.5M |
| Free Cash FlowOCF − Capex | $53.3M | $332.4M |
| FCF MarginFCF / Revenue | 5.4% | 55.5% |
| Capex IntensityCapex / Revenue | 6.7% | 0.2% |
| Cash ConversionOCF / Net Profit | — | 1.36× |
| TTM Free Cash FlowTrailing 4 quarters | $327.0M | $875.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $333.5M | ||
| Q4 25 | $183.7M | $290.3M | ||
| Q3 25 | $177.6M | $49.0M | ||
| Q2 25 | $126.0M | $211.4M | ||
| Q1 25 | $82.7M | $240.3M | ||
| Q4 24 | $178.2M | — | ||
| Q3 24 | $229.3M | $271.3M | ||
| Q2 24 | $143.6M | $119.5M |
| Q1 26 | $53.3M | $332.4M | ||
| Q4 25 | $96.9M | $288.8M | ||
| Q3 25 | $114.3M | $46.2M | ||
| Q2 25 | $62.5M | $208.5M | ||
| Q1 25 | $25.9M | $236.3M | ||
| Q4 24 | $112.2M | — | ||
| Q3 24 | $162.7M | $263.1M | ||
| Q2 24 | $75.4M | $113.0M |
| Q1 26 | 5.4% | 55.5% | ||
| Q4 25 | 10.1% | 48.3% | ||
| Q3 25 | 11.9% | 8.1% | ||
| Q2 25 | 6.5% | 37.5% | ||
| Q1 25 | 2.9% | 41.7% | ||
| Q4 24 | 13.2% | — | ||
| Q3 24 | 17.9% | 48.8% | ||
| Q2 24 | 8.3% | 17.7% |
| Q1 26 | 6.7% | 0.2% | ||
| Q4 25 | 9.0% | 0.2% | ||
| Q3 25 | 6.6% | 0.5% | ||
| Q2 25 | 6.6% | 0.5% | ||
| Q1 25 | 6.4% | 0.7% | ||
| Q4 24 | 7.8% | — | ||
| Q3 24 | 7.3% | 1.5% | ||
| Q2 24 | 7.5% | 1.0% |
| Q1 26 | — | 1.36× | ||
| Q4 25 | 2.47× | 1.50× | ||
| Q3 25 | 1.39× | 0.27× | ||
| Q2 25 | 1.13× | 1.32× | ||
| Q1 25 | 1.05× | 1.72× | ||
| Q4 24 | 1.77× | — | ||
| Q3 24 | 2.29× | 2.30× | ||
| Q2 24 | 1.59× | 0.53× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATR
Segment breakdown not available.
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
